Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
ImmuneIntelligence AB
AB
Active
Org 5591159776
Korsåkersvägen 53, 226 50
Lund
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2017 · 9 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
ImmuneIntelligence AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
2M
2M
1M
1M
0M
2020: 1M
1M
2020
2021: 2M (+100% vs 2020)
2M
+100%
2021
2022: 1M (-50% vs 2021)
1M
-50%
2022
2023: 0M (-100% vs 2022)
0M
-100%
2023
2024: 0M
0M
2024
EBITDA
SEK millions
1M
1M
1M
0M
0M
2020: 0M
0M
2020
2021: 1M
1M
2021
2022: 0M (-100% vs 2021)
0M
-100%
2022
2023: 0M
0M
2023
2024: 0M
0M
2024
Income statement
SEK thousands
Item
2024
2023
2022
2021
2020
Revenue
100
100
1 259
2 067
1 230
Staff expenses
—
—
—
—
—
EBITDA
−44
−25
83
934
475
Depreciation & amort.
−0
−0
−0
−0
−0
EBIT
−44
−25
83
934
475
Net financials
27
34
−6
−3
−1
Profit before tax
−17
8
78
931
475
Tax
−0
−1
−16
−193
−103
Net profit
−17
7
62
738
372
Balance sheet
SEK thousands
Item
2024
2023
2022
2021
2020
Total assets
1 820
1 963
2 531
2 715
1 628
Equity
1 055
1 272
1 865
1 803
1 065
Long-term debt
0
0
0
0
0
Short-term debt
765
691
667
912
563
Total debt
765
691
667
912
563
Financial ratios
5-year trend
EBITDA margin
−44,0 %
This company
15,8 %
Market median
This company
Market median
378% below market
2020
2024
Equity ratio
58,0 %
This company
38,2 %
Market median
This company
Market median
52% above market
2020
2024
Return on equity
−1,6 %
This company
18,4 %
Market median
This company
Market median
109% below market
2020
2024
Net profit margin
−17,0 %
This company
8,1 %
Market median
This company
Market median
310% below market
2020
2024
Asset turnover
0,05×
This company
1,12×
Market median
This company
Market median
96% below market
2020
2024
Debt / equity
0,73×
This company
0,62×
Market median
This company
Market median
18% above market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on ImmuneIntelligence AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
